Latest news with #bitXbio
Business Wire
5 days ago
- Business
- Business Wire
Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations,announced today that it has signed a custody agreement with a global leader in digital asset platforms, to establish a custodial crypto account. The agreement is a foundational step in the broader planned rollout of bitXbio™ —Aditxt's crypto-native social platform bridging Fintech and Biotech. Under the agreement will serve as the custodian for Aditxt's proposed digital treasury, supporting its planned strategy to back biotech innovation with a reserve of digital assets including Bitcoin. Additionally, ADTX common stock is now tradable through broker-dealer, providing a more seamless opportunity for crypto native retail and institutional investors to trade ADTX. Custody, institutional-grade custody offering, will provide the custodial services. Custody offers custody services to eligible institutions and high-net-worth clients through a comprehensive, end-to-end solution with safety and security at its core. 'Businesses across industries are strategically planning for the future with digital asset treasuries,' said Eric Anziani, President and Chief Operating Officer of 'We are pleased to support Aditxt and its pioneering bitXbio initiative with our best-in-class custodial capabilities and as they look to engage crypto native traders.' The initiative is part of Aditxt's bitXbio™ platform, which aims to expand access to innovations in immune reprogramming (Adimune), early cancer detection (Pearsanta), women's health (Adifem) and other innovations with the potential of addressing some of the most pressing health challenges. 'We believe that this agreement is a key step in aligning our biotech assets with a next-generation financial infrastructure,' said Amro Albanna, Co-founder and CEO of Aditxt. 'By engaging for custody and access, we are laying the foundation for a new kind of platform—where value is not only created through innovation but made accessible to all through digital finance.' About Founded in 2016, is trusted by more than 150 million customers worldwide and is the industry leader in regulatory compliance, security and privacy. Our vision is simple: Cryptocurrency in Every Wallet™. is committed to accelerating the adoption of cryptocurrency through innovation and empowering the next generation of builders, creators, and entrepreneurs to develop a fairer and more equitable digital ecosystem. About Aditxt, Inc. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.0 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," "advancing", "aim," "are working to," "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to anticipated availability of funds to pursue the purchase of digital assets; Aditxt's ability to successfully execute its mission to accelerate and monetize promising health innovations, and magnitude thereof; Aditxt's ability to complete the proposed initial public offering of Pearsanta on the proposed timeline, if at all; Aditxt's ability to close the planned acquisition of Evofem, including to meet all closing conditions, and the timing thereof; and anticipated availability of funds to pursue the purchase of digital assets by Aditxt. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law. For more information, please visit Follow Aditxt on:
Business Wire
07-07-2025
- Business
- Business Wire
Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced its bitXbio (pronounced 'bit by bio') Plan, a next-generation capitalization and monetization public-market strategy integrating Bitcoin (BTC) in support of its biotech commercialization efforts. The initiative will be anchored by a Bitcoin-backed treasury strategy that was recently approved by its board of directors, aimed at expanding Aditxt's capital ecosystem and aligning its enterprise value (EV) with projected monetization opportunities starting in 2026. Aditxt is a social innovation platform that currently operates two programs focused on autoimmunity and early disease and cancer detection. The Company seeks to grow by A cquiring, B uilding, and C apitalizing high-growth ventures across health and biotechnology. The bitXbio Plan marks a deliberate move to broaden the company's capital accessibility and align its current market value with its commercialization roadmap — blending Bitcoin-backed reserve with capital access to support scale and liquidity. 'bitXbio™ is a forward-looking strategy designed to align our capital structure with the value-creation potential of our biotech pipeline,' said Amro Albanna, Co-founder and CEO of Aditxt. 'As we look to strengthen our balance sheet and enterprise value, we plan to seek to integrate digital currency reserves, subject to the availability of funds, and continue to utilize our equity line to support the commercialization of high-impact innovations. We believe that this approach positions us to unlock shareholder value as we strive to execute on planned monetization milestones, starting in 2026.' Plan Highlights Bitcoin-Backed Treasury Strategy Aditxt plans to establish a Bitcoin reserve, subject to the availability of funds, to align its market value in support of its commercialization activities, and to unlock a new class of opportunities with digital asset economies. Equity Line Facility Aditxt intends to strategically deploy capital drawn on its existing equity line facility to meet its existing financial obligations and in support of its commercialization roadmap and upcoming monetization events. Aditxt has approximately $125 million in availability under its common stock purchase agreement with its equity line investor, of which it presently has the ability to sell up to 50 million shares of its common stock pursuant to its registration statement on Form S-1, which was declared effective by the SEC on June 30, 2025. Planned Capitalization Events in 2026 As part of its 2026 monetization strategy, Aditxt is positioning Pearsanta for an initial public offering. The plan reflects Aditxt's broader vision to build a global, socially driven biotech platform, capable of commercializing and monetizing innovation through digital capitalization. About Aditxt, Inc. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," "advancing," "aim," "are working to," "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to anticipated availability of funds to pursue the purchase of digital assets; expected growth of Aditxt; Aditxt's ability to successfully execute its mission to accelerate and monetize promising health innovations, and magnitude thereof; Aditxt's ability to complete the proposed initial public offering of Pearsanta on the proposed timeline, if at all; and Aditxt's ability to close the planned acquisition of Evofem, including to meet all closing conditions, and the timing thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 21, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law. For more information, please visit bitXbio™ is a trademark of Aditxt, Inc. All rights reserved. Follow Aditxt on:
